Lilly's Imlunestrant Phase 3 EMBER-3 Data to be Presented at SABCS 2024
核心洞察
Eli Lilly's Imlunestrant, an oral selective estrogen receptor (搜索) degrader (SERD), will have its Phase 3 EMBER-3 trial results presented at the San Antonio Breast Cancer (搜索) Symposium (SABCS).
The EMBER-3 trial evaluated Imlunestrant alone or combined with Verzenio (abemaciclib) in pretreated ER+, HER2- advanced breast cancer (搜索) patients.
Lilly will also share real-world data on recurrence risk in HR+, HER2- early breast cancer (搜索) and preclinical data for next-gen PI3Ka (搜索) inhibitor LY4045004 (搜索).
Eli Lilly and Company will present data from the Phase 3 EMBER-3 trial of imlunestrant, an oral selective estrogen receptor (搜索) degrader (SERD), at the San Antonio Breast Cancer (搜索) Symposium (SABCS) in December. The EMBER-3 trial focuses on estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
The study investigates imlunestrant as a monotherapy and in combination with Verzenio (abemaciclib), a CDK4/6 (搜索) inhibitor, in patients previously treated with endocrine therapy, with or without a CDK4/6 inhibitor. The presentation (GS1-01) by Komal Jhaveri is scheduled for December 11, 2024, at 9:15-9:30 a.m. CST in Hall 1.
Additional Breast Cancer Data Presentations
In addition to the EMBER-3 data, Lilly will present a real-world analysis of recurrence risk based on nodal status and high-risk features in patients with hormone receptor-positive (HR+), HER2- early breast cancer (搜索). Sara Tolaney will present this analysis (P1-11-02) on December 11, 2024, from 12-2 p.m. CST in Halls 2-3.
Further presentations will cover investigational mutant selective PI3Ka (搜索) inhibitor assets, including preclinical characterization data for LY4045004 (搜索), expected to enter clinical trials in the first half of 2025. Phase 1a/b clinical data for LOXO-783, a predecessor molecule that informed the development of LY4045004, will also be shared. Raymond Gilmour (Lilly) will present the LY4045004 data (P4-12-24) on December 12, 2024, from 5:30-7 p.m. CST in Halls 2-3, while Komal Jhaveri will present LOXO-783 data (PS7-03) on December 11, 2024, from 7-8:30 a.m. CST.
Verzenio (abemaciclib) Presentations
Lilly will also present several abstracts related to Verzenio (abemaciclib), a CDK4/6 (搜索) inhibitor approved for HR+, HER2- breast cancers. These include:
- Genomic profiling of ctDNA and association with efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy (P1-01-26).
- Clinical Characteristics and Treatment Persistence in US Patients with HR+/HER2-, Node Positive Early Breast Cancer Treated with Abemaciclib: Real-World Study from First Year After Approval (P1-11-29).
- Unveiling the Antitumor Mechanism of abemaciclib in Human Breast Cancer Through Circulating Tumor Chromatin Analysis (P5-02-23).
About Imlunestrant
Imlunestrant is an oral selective estrogen receptor (搜索) (ER) degrader designed to provide continuous ER inhibition, including in ESR1-mutant cancers. It is currently under investigation for advanced breast cancer (搜索) and as an adjuvant treatment in early breast cancer.
About Verzenio (abemaciclib)
Verzenio is a CDK4/6 (搜索) inhibitor approved for certain HR+, HER2- breast cancers in both adjuvant and advanced/metastatic settings. It is the first CDK4/6 inhibitor approved for node-positive, high-risk early breast cancer (搜索). It functions by blocking CDK4 and CDK6, preventing cell cycle progression and tumor growth.